CTCF and prostate cancer: The significant association of elevated CTCF expression with unfavorable tumor phenotype, including high Gleason grade, advanced tumor stage, presence of lymph node metastasis (P ≤ 0.0002, each), accelerated cell proliferation (P < 0.0001), and early biochemical recurrence (P ≤ 0.001), argues for a role of CTCF for prostate cancer progression and aggressiveness.